cyrilzakka/clinical-trials huggingface dataset:
Reducing Pain Intensity During Spinal Needle Insertion: Valsalva Maneuver vs. Control Technique

This study was aimed to observe the efficacy of Valsalva maneuver in reducing pain intensity during spinal needle insertion.

Spinal anesthesia is one of the regional anesthesia techniques needed to provide motor, sensory, and autonomic blocks specifically for lower limbs by delivering local anesthetics into subarachnoid space. This technique is not difficult to perform and relatively inexpensive. However, spinal anesthesia may cause an intense pain during needle insertion. Valsalva maneuver is an attempt to force expiration by pushing a closed airway, such as covering nose or mouth. This maneuver can lead to anti-nociceptive stimulation and may decrease the pain. Thus, this study was aimed to observe the efficacy of Valsalva maneuver in reducing pain intensity during spinal needle insertion.

Eligibility Criteria:
Inclusion Criteria:

* Elective patients having spinal anesthesia
* Patients with no previous history of spinal anesthesia
* Patients with criteria of American Society of Anaesthesiologist (ASA) I-II
* Patients willing to participate in the study and signing informed consent form

Exclusion Criteria:

* Patients with contraindications of spinal anesthesia
* Patients with difficulty in blowing 30 mmHg for 20 seconds
* Patients having allergic reactions due to local anesthetics and opioid
Clinical Results of Small Incision Lenticule Extraction (SMILE) for the Correction of High Myopia

Small Incision Lenticule Extraction (SMILE) was introduced in 2011 using the VISUMAX femtosecond laser (Carl Zeiss Meditec, Jena, Germany). It is designed for correction of myopia and myopic astigmatism.

It involves the creation of a corneal tissue disk called lenticule and its extraction through a minimally invasive incision, utilizing only a femtosecond laser. This enables rapid visual recovery with very little discomfort to the patient.

This observational case series monitors visual and refractive outcomes of myopic correction for more than -7.75 D.

It is to

* gather long-term results and refractive stability
* detect rare complications or side-effects
* evaluate the efficacy in a large number of patients


Eligibility Criteria:
Inclusion Criteria:

* adults
* myopia more than -7.75 D
* refractive stability more than 1 year

Exclusion Criteria:

* corneal irregular astigmatism
* ectatic conditions
Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment

The purpose of this this study, to evaluate the quality of sexual life of patients treated for anal cancer treated by radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after treatment. cancer diagnosis.

Sexual health is defined by WHO in 2011 as a state of physical, emotional, mental and social well-being in relation to sexuality. It is an integral part of health, well-being and quality of life and is recognized as a right of everyone.Alteration of sexuality after cancer impacts all phases of the sexual response. It is multifactorial: psychological (ie, anxiety linked to the disease, fear of death, or impairment of body image) and physiological (ie, alteration of the sexual reaction which may be linked, in part, to direct sequelae generated by irradiation of the genitals).

Anal cancer remains fairly rare, affecting around 2,200 people each year in France, with a predominance of women (60 to 70% of patients), However, its incidence has been growing strongly for 30 years, in Europe and the United States where it is has increased by 70% over the last 10 years alone, in both men and women, with an increasingly younger population.

It is linked, in more than 90% of cases, to a carcinogenic virus, the Human PapillomaVirus (HPV), a late consequence of an infection, most often asymptomatic, transmitted by the sexual route.

The question of sexuality after cancer remains, in fact, very little addressed by doctors who express a lack of training. Patients, for their part, often do not dare to raise the issue with caregivers, out of modesty, or thinking that the teams do not have the time. Discussions with patients therefore generally always remain focused on oncological management, from the initial consultation to the follow-up consultations. The hope of recovery awaited on each of the assessments and the fear of relapse often obscure more global and equally essential questions: whether it is about the quality of life, the after-effects, or even more, the quality. of sex life. For these reasons, this study will collect the information provided to patients on the impact of this treatment on their sexual health, whether it is medical information recorded in the file, or information perceived and retained by patients.

Eligibility Criteria:
Inclusion Criteria:

1. Age\> 18 years old.
2. Patient treated for non-metastatic squamous cell anus cancer with the presence of an HPV infection authenticated on the biopsy.
3. Patient living with a partner or having an active sex life the year preceding the diagnosis.
4. Patient who, after information, agrees to participate in the study.
5. Patient affiliated to a French social security scheme.

Exclusion Criteria:

1. Patient unable or unwilling to complete a questionnaire on the quality of sexual life.
2. Patient without sexual activity the year before diagnosis.
3. Patient whose regular follow-up is impossible for psychological, family, social or geographic reasons.
4. Patient under guardianship, curatorship or legal protection.
Proximal and Distal Approach GON RFT in Migraine

Greater occipital nerve pulsed radiofrequency therapy is used in the treatment of migraine. This method is applied at the level of the proximal c2 vertebra and by approaching the nerve from the distal 1/3 medial of the occipital protuberant. The investigators aimed to compare the effectiveness of these two methods.

Greater occipital nerve (GON) pulsed radiofrequency application is used in migraine headaches. The procedure is applied by approaching the occipital nerve trace with a radiofrequency needle, giving a pulsed radiofrequency current for 4 minutes, and then injecting 2.5 cc bupivacaine and saline. There are two types of applications. In the proximal/central approach, the injection is administered to the occipital nerve between the semispinalis capitis muscle and the obliquus capitis inferior, under ultrasound guidance, while in the distal approach, it is administered 1/3 cm medial to the occipital protuberant with a blind technique.

The investigators aim to compare the treatment response at 1 and 3 months between two patient groups treated with both methods. For this purpose, The investigators planned to follow up with 60 patients. GON RF will be performed with a proximal approach to half of the patients and a distal approach to the other half. Pain levels will be measured on the Visual Analogue Scale (VAS) in the 1st and 3rd months after the procedure. Migraine Disability Index (MIDAS) will be applied to the patients in the 1st week and 3rd month after the procedure. Thus, it will be determined whether there is a difference between the approaches in terms of pain palliation.

Patients who have undergone the procedure will be found from their file records and called by phone, when they come to the control, face to face and 1-3. In the months, the scales will be filled by calling by phone.

Eligibility Criteria:
Inclusion Criteria:

* Primary migraine hedache, first interventional treatment for headache

Exclusion Criteria:

* Preganancy, malignancy
Diaphragmatic Thickening Fraction as a Predictor of Successful Weaning

The aim of this study is to assess the validity of the diaphragmatic thickening Fraction measured by ultrasound as a predictor for successful weaning from mechanical ventilation.

Timing is critical for proper weaning for patients undergoing mechanical ventilation; if this is performed prematurely complications can include increased cardiovascular and respiratory stress, CO2 retention and hypoxemia. However, unnecessary delay in weaning can also cause a number of side-effects.Weaning outcomes have been assessed by several indices. Variables such as minute ventilation, Pao2/Fio2, rapid shallow breathing index and static compliance have all been used, with variable predictive values. Previous studies have proved that diaphragmatic dysfunction is one of the main etiologies of difficult weaning, because the diaphragm progressively weakens with mechanical ventilation.Methods used to assess diaphragm function, such as fluoroscopy, phrenic nerve stimulation, measurement of trans-diaphragmatic pressure and dynamic magnetic resonance imaging of the diaphragm, all have limitations. These include ionizing radiation exposure, low availability, invasiveness and necessity for patient transportation. Conversely, the use of ultrasound is safe, non-invasive, avoids radiation side-effects, and is available at the bedside.The aim of this study is to assess the validity of the diaphragmatic thickening Fraction measured by ultrasound as a predictor for successful weaning from mechanical ventilation.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients \>18 years old, who are in need for mechanical ventilation as: Life threatening hypoxia, Respiratory rate \> 30 breath/min, Disturbed conscious level.

Exclusion Criteria:

* Age \<18 years.
* Pregnancy
* Surgical incisions likely to interfere with ultrasound examination.
* Hepato-splenomegaly, Ascites
* Neuromuscular disease as Myasthenia gravis, kypho-scoliosis
* Diaphragmatic Paralysis (paralyzed diaphragm exhibiting abnormal paradoxical movement, i.e., moving in a cranial direction during inspiration
BCRL Prevention Pilot

The purpose of this study is to establish feasiblity of recruiting obese breast cancer survivors at the end of treatment, getting those survivors to lose weight and attend follow-up visits for 6 months.

Breast cancer related lymphedema occurs in 20-30% of survivors. Weight loss could prevent onset. We seek to do a pilot study to establish feasibility of 1) recruiting survivors at risk for lymphedema to do a weight loss intervention, 2) achieving 10-15% weight loss over 26 weeks in this population, and 3) attendance at follow-up visits 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Women
* Breast Cancer Survivors who had 5 or more lymph nodes removed and radiation to lymph nodes as part of treatment.
* Completed all treatments - no metastatic cancers
* Overweight or obese (BMI greater than or equal to 25 kg/m2)
* Medically and logistically able to participate in a weight loss and exercise program over 6 months.
* Diagnosed with breast cancer within the past 2 years.

Exclusion Criteria:

* More than 2 years since breast cancer diagnosis
* Medical status that would preclude safety of participation in a weight loss and exercise program
* Metastatic cancer
* Already enrolled in a weight loss program
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid nitrogen sprayed through a catheter via flexible fiber optic bronchoscopy (FFB)

The proposed study is a single center pilot study consisting of up to 10 subjects with benign airway disease. Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment at Day 0. Subjects will undergo repeat bronchoscopy in the first three to seven days after the initial treatment, to check for mucosal sloughing and to reassess luminal patency of the airway. Subjects may undergo up to one bronchoscopy per week with CSA therapy for a total of four (4) treatments in the first month. If they present with symptoms thereafter, then a repeat bronchoscopy will be performed; if luminal obstruction is noted, then the subject will begin the treatment protocol again. If disease exists bilaterally, only one side will be sprayed initially.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age
* Deemed a candidate for cryotherapy based on physician physical or medical history review
* Deemed operable based on institutional criteria.

Exclusion Criteria:

* Pregnant or nursing
* Planning to sire a child while enrolled in the study
* Known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines.
* Refusal or inability to give consent.
* Concurrent chemotherapy.
* Prior radiation therapy which involved the any area between the vocal chords and the diaphragm
* Medical contraindication or potential problem that would preclude study participation
* Concurrent participation in other experimental studies Uncontrolled coagulopathy or bleeding diathesis

Serious medical illness, including:

* Uncontrolled congestive heart failure
* Uncontrolled angina
* Myocardial infarction
* Cerebrovascular accident within 6 months prior to study entry
Needle Stick Injuries in Emergency Medical Service Practice

During the pandemic era, medical personnel should wear full protective suits. However, they limit the performance of medical procedures. One of the main questions is whether to use double gloves. The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.


Eligibility Criteria:
Inclusion Criteria:

* Give voluntary consent to participate in the study
* Medical profession (paramedics, nurses, physicians) working in Emergency Medical Service

Exclusion Criteria:

* Not meet the above criteria
* Wrist or low back diseases
PUL vs TURP in BPH Patients With Urinary Retention

The study will be a prospective, randomized controlled trial comparing prostatic urethral lift (PUL) versus transurethral resection of prostate (TURP) in benign prostate hyperplasia (BPH) patients with urinary retention. The primary objective of this study is to compare the catheter-free rates of PUL vs TURP. Secondary objectives include comparison of complications rates, cost effectiveness, patient satisfactory, symptom scores, quality of life measures and urodynamic parameters.

The study will be a prospective, non-inferiority randomized controlled trial with the aim of detecting a non-inferiority margin of 5%.

After the potential subject has been informed of the study and the potential risks, he will be screened for eligibility within a 4 week period. Assessment of eligibility will include questionnaires, blood tests, urine tests, uroflowmetry, flexible cystoscopy, transrectal ultrasound, and urodynamic study. Suitable subjects will then be randomized in a 1:1 ratio to the prostatic urethral lift (intervention group) and TURP (control group). Patients in the prostatic urethral lift will have the procedure performed under local anesthesia or monitored anesthetic care while TURP patients will be performed under spinal or general anesthesia. The subjects will have regular follow up 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years post-operatively. Follow up assessments will include questionnaires, uroflowmetry, and occasional urodynamic study.

Eligibility Criteria:
Inclusion Criteria:

* Male patients
* age \>40 years old
* urinary retention who failed trial without catheter

Exclusion Criteria:

* Inability to provide consent OR no guardians or relatives to help provide consent on patient's behalf
* Active urinary tract infection
* Previous surgical treatment for benign prostatic hyperplasia (i.e., TURP, prostatic urethral lift, etc.)
* Bladder stones
* Urethral strictures or bladder neck contractures
* Prostate size \>100mL
* Solely obstructing median lobe
* Urinary retention not due to obstruction (i.e., Bladder outflow obstruction index \<20 on urodynamic studies)
* Poor detrusor contractility (maximum detrusor pressure \<20cmH2O during voiding phase)
* Anticoagulant or antiplatelet agents that cannot be stopped
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

The purpose of this clinical research study is to learn if BMS-354825 will have activity, defined by hematologic response, in subjects who have accelerated phase chronic myeloid leukemia (CML) who are resistant to or intolerant to imatinib mesylate. The safety of this treatment will also be studied.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with Philadelphia chromosome positive (PH+) or the fused gene BCR/ABL positive (BCR/ABL+) accelerated phase chronic myeloid leukemia (CML) whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate.
* Subjects must have had prior exposure to imatinib. However, imatinib mesylate does not need to be their most recent CML treatment prior to coming on this study.
* Men and women, 18 years of age or older.
* Adequate hepatic function.
* Adequate renal function.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

* Women who are pregnant or breastfeeding.
* Subjects who are eligible and willing to undergo transplantation during the screening period.
* A serious uncontrolled medical disorder or active infection that would impair the ability of the subjects to receive protocol therapy.
* Uncontrolled or significant cardiovascular disease.
* Medications that increase bleeding risk.
* Medications that change heart rhythms.
* Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.
* History of significant bleeding disorder unrelated to CML.
* Concurrent incurable malignancy other than CML.
* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy.
* Prior therapy with dasatinib (BMS-354825).
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
FLACS vs Phaco in Shallow Anterior Chamber

Phacoemulsification in eyes with a shallow anterior chamber (ACD \< 2.2mm) presents with problems of safe access to the cataract and increased vulnerability of the endothelium and a higher tendency of complications such as descemet's detachment and iris prolapse. A shallow anterior chamber is also responsible for the high incidence of glaucoma and postoperative complications after cataract surgery. Femtosecond assisted cataract surgery has made cataract surgery safer and more predictable. The effective phacoemulsification time and intra-operative manipulation is greatly reduced in FLACS. However phacoemulsification still remains the most widely performed cataract surgery around the world. Post-operative outcomes after phacoemulsification in patients having shallow anterior chamber have been extensively reported in literature over the years.

There is no head to head comparison in terms of intraoperative performance and post-operative outcomes between FLACS and phacoemulsification in eyes with shallow anterior chamber.

The aim is to compare the intra-operative performance and post-operative outcomes in eyes undergoing femtosecond laser assisted cataract surgery versus eyes undergoing phacoemulsification in eyes having shallow anterior chamber.

The study will bring an understanding on the question: Do patients undergoing Femtosecond laser assisted cataract surgery behave differently from those undergoing phacoemulsification?

Inclusion Criteria:

* Age-related cataract
* Shallow Anterior Chamber (\<2.5mm)

Exclusion Criteria:

-Ocular co-morbidity - corneal disorders, glaucoma, uveitis, previous ocular surgery

Surgical Technique :

* Standardized, Single Surgeon
* 2.2 mm clear corneal temporal incision
* FLACS Group : Capsulorhexis, Lens Fragmentation with femto laser

The investigators will be evaluating the following parameters:

1. Primary outcome measure Corneal thickness on day 1, week 1 and 1 month (Change in corneal thickness of 15% from preop. will be considered significant).
2. Secondary outcome measures

   * Corneal clarity -on day 1, week 1 and 1 month postoperatively
   * Anterior chamber cells and flare (Hogan's criteria)
   * Percentage change in endothelial cell density from preoperatively to 3 months postoperatively
   * Unaided visual acuity (distance) on day 1 and 1 month.
   * Best corrected distance visual acuity 1 month postoperatively
3. Other Observations :

1) Cumulative Dissipated Energy (CDE) 2) Surgical time 3) Fluid used 4) Descemets membrane detachment during surgery 5) Incidence of iris trauma 6) Any other intra-operative complications

Eligibility Criteria:
Inclusion Criteria:

* uncomplicated, age related cataracts
* Shallow anterior chamber (measured as \</=2.5mm )

Exclusion Criteria:

* Coexisting ocular morbidity,
* inability to come for followup
Clear Aligner Treatment With and Without Low Level Laser Therapy for Upper Incisor Crowding

The goal of this clinical trial is to assess the effect of Low Level Laser Therapy (LLLT) on Upper Incisor Crowding using Clear Aligner Treatment (CAT).

The goal of this clinical trial is to assess the effect of Low Level Laser Therapy (LLLT) on Upper Incisor Crowding using Clear Aligner Treatment (CAT) on healthy patients (16-23 years old) with complete set of dentition and Angle class I. The main questions to answer are:

1. Evaluate rate of Upper Incisor Decrowding using CAT and LLLT
2. Does LLLT affect pain during CAT?

Researchers will compare CAT with LLLT to CAT without LLLT to see if the LLLT will accelerate Orthodontic Tooth Movement.

Participants will:

* Change to a new aligner every 7 days.
* Visit the clinic every week for checkup.
* Log in pain scores every 6, 24, 48 and 72 hours after delivery of new aligners.

Eligibility Criteria:
Inclusion Criteria:

1. Patients age ranging from 16-23 years old with Angle class I malocclusion and upper anterior crowding.
2. Healthy, compliant and internally motivated patient.
3. Full set of maxillary permanent dentition except third molar.

Exclusion Criteria:

1. Previous orthodontic treatment.
2. Any systemic diseases that could interfere with orthodontic treatment.
3. Gross gingival or periodontal problems